These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36066204)

  • 1. Conditioning with melphalan 200 mg/m
    Afram G; Chaireti R; Uttervall K; Luong V; Lund J; Kashif M; Gahrton G; Alici E; Nahi H
    Eur J Haematol; 2022 Dec; 109(6):749-754. PubMed ID: 36066204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
    Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
    Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
    Veeraputhiran M; Jain T; Deol A; Ayash L; Kim S; Dyson G; Bhutani D; Lum LG; Ratanatharathorn V; Uberti JP; Abidi MH
    Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):531-5. PubMed ID: 26166312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
    Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
    Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Melphalan 200 mg/m
    Brioli A; Vom Hofe F; Rucci P; Ernst T; Yomade O; Hilgendorf I; Scholl S; Sayer H; Mügge LO; Hochhaus A; von Lilienfeld-Toal M
    Bone Marrow Transplant; 2021 May; 56(5):1209-1212. PubMed ID: 33299059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A Propensity Score Matching Study of Autologous Hematopoietic Stem Cell Transplantation and New Drug Chemotherapy for Newly Diagnosed Multiple Myeloma].
    Yang FY; Wang HF; Xia LH; Wang QQ; Qian CJ; He J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):158-165. PubMed ID: 35123620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing Outcomes in Patients With Multiple Myeloma Postautologous Stem Cell Transplantation: Contrasting the Effects of Melphalan Dosages at 200 mg/m
    Brown Z; Scott C; Zhang LF; Sadek R; Clarke A; Jillella A; Keruakous AR; Clemmons AB
    Clin Lymphoma Myeloma Leuk; 2024 Sep; 24(9):642-647. PubMed ID: 38845275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of melphalan 140 mg/m(2) vs 200 mg/m(2) on toxicities and outcomes in multiple myeloma patients undergoing single autologous stem cell transplantation-a single center experience.
    Katragadda L; McCullough LM; Dai Y; Hsu J; Byrne M; Hiemenz J; May S; Cogle CR; Norkin M; Brown RA; Wingard JR; Chang M; Moreb JS
    Clin Transplant; 2016 Aug; 30(8):894-900. PubMed ID: 27219740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A
    Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care.
    Bostankolu Değirmenci B; Yegin ZA; Akdemir ÜÖ; Dede A; Gündem GG; Özkurt ZN; Atay LÖ; Yağcı M
    Ann Hematol; 2024 Jan; 103(1):269-283. PubMed ID: 37880484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
    Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
    Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage bortezomib-dexamethasone and high-dose melphalan (HDM) and autologous stem cell support (ASCT) in myeloma patients at first relapse after HDM with ASCT. A phase-2 trial.
    Gimsing P; Hjertner Ø; Abildgaard N; Andersen NF; Dahl TG; Gregersen H; Klausen TW; Mellqvist UH; Linder O; Lindås R; Tøffner Clausen N; Lenhoff S
    Bone Marrow Transplant; 2015 Oct; 50(10):1306-11. PubMed ID: 26121108
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcomes following autologous stem cell transplant with melphalan 140mg/m
    Sharma N; Benson E; Zhao Q; Nunnelee J; Cottini F; Elder P; Rosko A; Bumma N; Khan A; Umyarova E; Devarakonda S; Efebera YA; Benson DM
    Leuk Lymphoma; 2023; 64(7):1315-1321. PubMed ID: 37199099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
    Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy.
    Martino M; Tripepi G; Messina G; Vincelli ID; Console G; Recchia AG; Gentile M; Molica S; Morabito F
    Bone Marrow Transplant; 2016 Sep; 51(9):1197-203. PubMed ID: 27088375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma.
    Miller KC; Gertz MA; Buadi FK; Hayman SR; Wolf RC; Lacy MQ; Dispenzieri AA; Dingli D; Kapoor P; Gonsalves WI; Kourelis T; Hogan WJ; Kumar SK
    Bone Marrow Transplant; 2019 Apr; 54(4):587-594. PubMed ID: 30116014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second autologous stem cell transplant: an effective therapy for relapsed multiple myeloma.
    Singh Abbi KK; Zheng J; Devlin SM; Giralt S; Landau H
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):468-72. PubMed ID: 25529381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.
    Takamatsu H; Takezako N; Zheng J; Moorhead M; Carlton VEH; Kong KA; Murata R; Ito S; Miyamoto T; Yokoyama K; Matsue K; Sato T; Kurokawa T; Yagi H; Terasaki Y; Ohata K; Matsumoto M; Yoshida T; Faham M; Nakao S
    Ann Oncol; 2017 Oct; 28(10):2503-2510. PubMed ID: 28945825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.